The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.

Extraintestinal manifestations of inflammatory bowel disease affect the musculoskeletal, dermatologic, ocular, renal and pulmonary systems.

Newly diagnosed hypertension in a patient whose blood pressure is 152/94 mm Hg. What agents will you consider for this patient? Beta-blockers? Think again.

(AUDIO) US Preventive Services Task Force recommendations for HIV screening may come into line with CDC guidelines thanks to a reanalysis of recent outcomes data. Here clinical epidemiologist Roger Chou MD, who conducted the analysis, describes the new evidence and the implications.

PCSK-9 inhibition in patients with recalcitrant hypercholesterolemia has reaped reductions in LDL-C of up to 85% after the first week of therapy.

Data from an inner-city AIDS treatment clinic in Baltimore suggest that inequities in HIV/AIDS treatment may be undergoing a necessary correction. In this podcast, an author of the study explains what this may mean for people in treatment elsewhere.

Platelet function monitoring and adjustment of treatment based on results after coronary stenting does not improve clinical outcomes . . . and other findings from the AHA Scientific Sessions.

Could intrathecally administered methotrexate be a viable treatment option for your patients with progressive forms of multiple sclerosis?

What is a safe, effective, and inexpensive way to reduce the risk of heart attacks, strokes, and dementia? What we eat is a key part of the answer. For one thing, doctors can suggest an appropriate diet to motivated patients, or to those who prefer a non-drug approach.

(AUDIO) There are disparities in the sensitivities and specificities of glucose and lactose hydrogen breath tests used to diagnose small intestine bacterial overgrowth and to distinguish patients with irritable bowel syndrome from healthy individuals. Just how useful are these tests? Insights from an expert here.

(AUDIO) Here, Christina Surawicz, MD, describes an organized approach to the evaluation and management of patients with chronic diarrhea.

A new analysis of data from a large international registry finds that use of beta-blockers in patients with and without a history of coronary artery disease does not reduce cardiovascular events.

(AUDIO) According to the Centers for Disease Control, more than one-third of US adults are obese. The CDC also estimates that as many as 1.4 million Americans suffer from inflammatory bowel disorder. So is there a link?

(AUDIO) What is the natural history of systemic corticosteroid therapy in ulcerative colitis? Insights here from Dr Nabeel Khan, Assistant Professor of Medicine in Gastroenterology & Hepatology at Tulane Medical Center-author of a new study on this topic.

At an "exciting" time in HIV treatment, the Affordable Care Act offers the prospect of immediate treatment for newly diagnosed HIV. In this podcast, the author of a new report on the topic discusses how the Act will affect your patients' care.

In 2000, MI was defined as any necrosis in the setting of myocardial ischemia. The 2007 update to this definition recognized that different conditions can lead to myocardial necrosis and 5 types of myocardial infarctions were defined.

It is high season for this potentially deadly viral infection, cases of which have been reported in every state. Will you be prepared? Guidance here from an expert.

For two HIV-positive patients, treatments with bone marrow transplants for cancer have achieved eradication of the virus from their blood cells. Learn in this podcast what this portends for the future.

Dr Farris Timimi, Assistant Professor of Medicine at the Mayo Clinic and Medical Director of the Mayo Clinic Center for Social Media, discusses the potential of social media to change the landscape of clinical practice.

Omega-3 fatty acids used to treat patients with dysglycemia in the ORIGIN trial failed to reduce cardiovascular death or ischemic events. Follow-up was 6 years.